Harmony Biosciences Holdings (HRMY) FCF Margin (2020 - 2026)
Harmony Biosciences Holdings (HRMY) posted FCF Margin of 12.89% for Q1 2026, down 75.07% sequentially from 51.7% in Q4 2025, and down 544.0% YoY from 2.9% in Q1 2025.
Harmony Biosciences Holdings (HRMY) FCF Margin (2020 - 2026) Analysis & Trends
Harmony Biosciences Holdings has reported FCF Margin for 7 years, with the latest figure at 12.89% in Q1 2026.
- Quarterly FCF Margin fell 544.0% year-over-year to 12.89% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 38.01% (up 829.0% YoY) and the FY2025 annual result came in at 40.06%, up 946.0% from the prior year.
- FCF Margin declined to 12.89% in Q1 2026 per HRMY's latest filing, from 51.7% in the prior quarter.
- Over five years, FCF Margin peaked at 51.7% in Q4 2025 and troughed at 12.89% in Q1 2026.
- A 5-year average of 33.45% and a median of 35.73% in 2023 frame the typical range for FCF Margin.
- The sharpest annual moves came in 2022 and 2023: FCF Margin sank 2036 bps in 2022, then jumped 2467 bps in 2023.
- Over 5 years, FCF Margin stood at 20.79% in 2022, then soared by 119 bps to 45.46% in 2023, then retreated by 18 bps to 37.29% in 2024, then jumped by 39 bps to 51.7% in 2025, then tumbled by 75 bps to 12.89% in 2026.
- According to Business Quant data, FCF Margin over the past three periods registered 12.89%, 51.7%, and 45.38% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 30.39% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 13.35% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 25.68% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -77,594.17% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 70.82% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 22.62% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -22.35% |
| 10 | Harmony Biosciences Holdings | 2.22 Bn | 1.41 Bn | 198.08 Mn | 35.38% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 35.38% |
| Mar 31, 2026 | 12.89% |
| Dec 31, 2025 | 51.70% |
| Sep 30, 2025 | 45.38% |
| Jun 30, 2025 | 39.56% |
| Mar 31, 2025 | 18.33% |
| Dec 31, 2024 | 37.29% |
| Sep 30, 2024 | 37.89% |
| Jun 30, 2024 | 24.29% |
| Mar 31, 2024 | 20.14% |
| Dec 31, 2023 | 45.46% |
| Sep 30, 2023 | 39.37% |
| Jun 30, 2023 | 27.61% |
| Mar 31, 2023 | 35.73% |
| Dec 31, 2022 | 20.79% |
| Sep 30, 2022 | 47.03% |
| Jun 30, 2022 | 31.48% |
| Mar 31, 2022 | 33.77% |
| Dec 31, 2021 | 41.15% |
| Sep 30, 2021 | 37.57% |